Adicet Bio, Inc. (fka resTORbio, Inc.)

Targeting aging-related diseases

Developer of medicines created to treat aging-related diseases and conditions. The company's therapies for aging-related diseases address conditions caused by immunosenescence while addressing the impairments of the brain, gut and immune systems, enabling doctors to re-establish T-cell composition and function, which in turn can revitalize immune homeostasis. In April 2020, ResTORbio and Adicet Bio, Inc., a privately-held biopharmaceutical company, announced that they had entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet